An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Intervention: Ontamalimab; Placebo
Intervention description: Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).; Participants will receive 1 mL of sterile aqueous buffered solution.
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 366.0
Sex: All
Minimum age: 16 Years
Maximum age: 81 Years
Healthy volunteers: No
Keywords: Ulcerative colitis

Summary:

      The purpose of this study is to evaluate the efficacy of ontamalimab as maintenance therapy
      treatment of remission, based on composite score of patient-reported symptoms and centrally
      read endoscopy, in participants with moderate to severe ulcerative colitis (UC).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants and/or their parent or legally authorized representative must have an
             understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          -  Participants must be able to voluntarily provide written, signed, and dated
             (personally or via a legally authorized representative) informed consent and/or
             assent, as applicable, to participate in the study.

          -  Participants must have completed the 12-week induction treatment period (SHP647-301
             [NCT03259334] and SHP647-302 [NCT03259308]).

          -  Participants must have achieved clinical response in induction study (SHP647-301
             [NCT03259334] and SHP647-302 [NCT03259308]). Clinical response is defined as:

             i) A decrease from the induction study (SHP647-301 [NCT03259334] and SHP647-302
             [NCT03259308]) baseline in the composite score of patient reported symptoms using
             daily e-diary and centrally read endoscopy of at least 2 points and at least 30
             percent (%), with an accompanying decrease in the sub score for rectal bleeding
             greater than or equal to (>=) 1 point or a sub score for rectal bleeding less than or
             equal to (<=) 1 OR ii) A decrease from the induction study (SHP647-301 [NCT03259334]
             and SHP647-302 [NCT03259308]) baseline in total Mayo score of at least 3 points and at
             least 30%, with an accompanying decrease in the rectal bleeding sub score of at least
             1 point or an absolute rectal bleeding sub score of 0 or 1.

        For eligibility assessment, clinical response will be determined based on the centrally
        read endoscopy performed during screening and at Week 12 of induction study (SHP647-301
        [NCT03259334] and SHP647-302 [NCT03259308]).

        - Participants receiving any treatment(s) for ulcerative colitis (UC) are eligible provided
        they have been, and are anticipated to be, on a stable dose for the designated period of
        time.

        Exclusion Criteria:

          -  Participants who had major protocol deviation(s) (as determined by the sponsor) in
             induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).

          -  Participants who permanently discontinued investigational product because of an
             adverse event (AE), regardless of relatedness to investigational product, in induction
             study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).

          -  Participants who are likely to require surgery for UC during the study period.

          -  Participants are females who became pregnant during induction study (SHP647-301
             [NCT03259334] and SHP647-302 [NCT03259308]), females who are planning to become
             pregnant during the study period, or males or females of childbearing potential not
             agreeing to continue using appropriate contraception methods (that is [i.e,] highly
             effective methods for female and medically appropriate methods for male study
             participants) through the conclusion of study participation.

          -  Participants who do not agree to postpone donation of any organ or tissue, including
             male participants who are planning to bank or donate sperm and female participants who
             are planning to harvest or donate eggs, for the duration of the study and through 16
             weeks after last dose of investigational product.

          -  Participants who, in the opinion of the investigator or the sponsor, will be
             uncooperative or unable to comply with study procedures.

          -  Participants who have a newly diagnosed malignancy or recurrence of malignancy (other
             than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in
             situ of the uterine cervix that has been treated with no evidence of recurrence).

          -  Participants who have developed any major illness/condition or evidence of an unstable
             clinical condition (example [eg], renal, hepatic, hematologic, gastrointestinal
             (except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg,
             Felty's syndrome], or local active infection/infectious illness) that, in the
             investigator's judgment, will substantially increase the risk to the participant if he
             or she participates in the study.

          -  Participants with any other severe acute or chronic medical or psychiatric condition
             or laboratory or electrocardiogram (ECG) abnormality that may increase the risk
             associated with study participation or investigational product administration or may
             interfere with the interpretation of study results and, in the judgment of the
             investigator, would make the participant inappropriate for entry into this study.

          -  Participants with known exposure to Mycobacterium tuberculosis (TB) since testing at
             screening in induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308])
             and who are without a generally accepted course of treatment.

          -  Participants who are investigational site staff members or relatives of those site
             staff members or participants who are sponsor employees directly involved in the
             conduct of the study.

          -  Participants who are participating in or plan to participate in other investigational
             studies (other than induction study SHP647- 301 [NCT03259334] and SHP647-302
             [NCT03259308]) during study SHP647-303 [NCT03290781].